|
EP2964227A2
|
|
Treatment and prophylaxis of kidney diseases
|
|
EP2731610A2
|
|
Pharmaceutical combination
|
|
SG195257A1
|
|
Anti-thrombotic compounds
|
|
KR20130101517A
|
|
Methods for the treatment or prophylaxis of thrombosis or embolism
|
|
EP2488180A2
|
|
Pharmaceutical compositions for the treatment/prophylaxis of non-alcoholic fatty liver disease
|
|
EP2467358A2
|
|
Novel complex for treatment and/or prophylaxis of parasitic infections
|
|
EP2446034A1
|
|
Novel polynucleotide molecules for enhanced gene expression
|
|
US2010081847A1
|
|
Process for preparation of atovaquone and novel intermediates thereof
|
|
EP2331099A1
|
|
Pharmaceutical compositions for the treatment of diabetes mellitus
|
|
WO2010041269A1
|
|
Process for preparation of mycophenolic acid, its salt and ester derivatives
|
|
WO2009122433A2
|
|
A process for preparation of ramipril
|
|
EP2203441A2
|
|
Process for optically active sulfoxide compounds
|
|
WO2010004573A1
|
|
Synergistic antimalarial pharmaceutical composition
|
|
WO2008120241A2
|
|
Novel alcohol solvates of perindopril erbumine
|
|
US2008207946A1
|
|
Process for preparation of highly pure isotretinoin
|
|
EP2114957A2
|
|
Process for preparation of crystalline clopidogrel hydrogen sulphate form i
|
|
EP1964836A2
|
|
A process for the preparation of perindopril erbumine in alpha crystalline form
|
|
US2008103334A1
|
|
Process For Synthesis Of Gabapentin
|
|
EP1803727A1
|
|
Improved process for manufacture of 4-amino-hydroxybutylidene-1,1-bisphosphonic acid and its salts
|
|
EP1785412A1
|
|
Tramadol recovery process
|
